Vir Biotechnology, Inc. Comprehensive Income
Vir Biotechnology, Inc. (VIR) reported Comprehensive Income of $78.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $78.96M.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$127.12M.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$43.07M.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$162.83M.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$438.33M.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$522.86M.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$606.75M, a 219.48% decline from fiscal 2022.
- Vir Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $507.81M, a 3.96% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $78.96M 10-Q · filed 2026-08-05 | -$48.16M 10-Q · filed 2026-08-05 | -$91.23M derived: sum of 3 quarters · filed 2026-08-05 | -$254.06M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$127.12M 10-Q · filed 2026-05-07 | -$170.19M derived: sum of 2 quarters · filed 2026-05-07 | -$333.02M derived: sum of 3 quarters · filed 2026-05-07 | -$444.23M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$43.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$205.90M derived: sum of 2 quarters · filed 2026-02-23 | -$317.10M derived: sum of 3 quarters · filed 2026-08-05 | -$438.33M 10-K · filed 2026-02-23 | |
| 2025-09-30 | -$162.83M 10-Q · filed 2025-11-05 | -$274.04M derived: sum of 2 quarters · filed 2026-08-05 | -$395.26M 10-Q · filed 2025-11-05 | -$502.69M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$111.20M 10-Q · filed 2026-08-05 | -$232.43M 10-Q · filed 2026-08-05 | -$339.86M derived: sum of 3 quarters · filed 2026-08-05 | -$549.57M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$121.22M 10-Q · filed 2026-05-07 | -$228.66M derived: sum of 2 quarters · filed 2026-05-07 | -$438.37M derived: sum of 3 quarters · filed 2026-05-07 | -$577.23M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$107.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$317.14M derived: sum of 2 quarters · filed 2026-02-23 | -$456.00M derived: sum of 3 quarters · filed 2026-02-23 | -$522.86M 10-K · filed 2026-02-23 | |
| 2024-09-30 | -$209.71M 10-Q · filed 2025-11-05 | -$348.57M derived: sum of 2 quarters · filed 2025-11-05 | -$415.43M 10-Q · filed 2025-11-05 | -$530.32M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | -$138.86M 10-Q · filed 2025-08-06 | -$205.72M 10-Q · filed 2025-08-06 | -$320.61M derived: sum of 3 quarters · filed 2026-02-23 | -$483.02M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | -$66.86M 10-Q · filed 2025-05-08 | -$181.75M derived: sum of 2 quarters · filed 2026-02-23 | -$344.16M derived: sum of 3 quarters · filed 2026-02-23 | -$538.62M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | -$114.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$277.30M derived: sum of 2 quarters · filed 2026-02-23 | -$471.76M derived: sum of 3 quarters · filed 2026-02-23 | -$606.75M 10-K · filed 2026-02-23 | |
| 2023-09-30 | -$162.41M 10-Q · filed 2024-11-04 | -$356.87M derived: sum of 2 quarters · filed 2024-11-04 | -$491.87M 10-Q · filed 2024-11-04 | -$590.71M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$194.46M 10-Q · filed 2024-08-01 | -$329.46M 10-Q · filed 2024-08-01 | -$428.30M derived: sum of 3 quarters · filed 2025-02-27 | -$257.32M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$135.00M 10-Q · filed 2024-05-03 | -$135.05M 10-Q · filed 2023-05-08 | -$233.84M derived: sum of 2 quarters · filed 2025-02-27 | -$62.86M derived: sum of 3 quarters · filed 2025-02-27 | -$142.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$98.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $72.14M derived: sum of 2 quarters · filed 2025-02-27 | -$7.10M derived: sum of 3 quarters · filed 2025-02-27 | $507.81M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $170.99M 10-Q · filed 2023-11-03 | $91.74M derived: sum of 2 quarters · filed 2023-11-03 | $606.66M 10-Q · filed 2023-11-03 | $1.13B derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | -$79.24M 10-Q · filed 2023-08-04 | $435.67M 10-Q · filed 2023-08-04 | $961.14M derived: sum of 3 quarters · filed 2024-02-26 | $1.07B derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $514.91M 10-Q · filed 2023-05-08 | $1.04B derived: sum of 2 quarters · filed 2024-02-26 | $1.15B derived: sum of 3 quarters · filed 2024-02-26 | $1.21B derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | $525.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $635.92M derived: sum of 2 quarters · filed 2024-02-26 | $697.70M derived: sum of 3 quarters · filed 2024-02-26 | $528.76M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $110.45M 10-Q · filed 2022-11-03 | $172.24M derived: sum of 2 quarters · filed 2022-11-03 | $3.30M 10-Q · filed 2022-11-03 | -$103.14M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $61.78M 10-Q · filed 2022-08-09 | -$107.15M 10-Q · filed 2022-08-09 | -$213.60M derived: sum of 3 quarters · filed 2023-02-28 | -$298.39M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | -$168.94M 10-Q · filed 2022-05-05 | -$275.38M derived: sum of 2 quarters · filed 2023-02-28 | -$360.18M derived: sum of 3 quarters · filed 2023-02-28 | -$391.89M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | -$106.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$191.24M derived: sum of 2 quarters · filed 2023-02-28 | -$222.95M derived: sum of 3 quarters · filed 2023-02-28 | -$299.34M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$84.80M 10-Q · filed 2021-11-04 | -$116.51M derived: sum of 2 quarters · filed 2021-11-04 | -$192.90M 10-Q · filed 2021-11-04 | -$257.35M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | -$31.71M 10-Q · filed 2021-08-05 | -$108.10M 10-Q · filed 2021-08-05 | -$172.55M derived: sum of 3 quarters · filed 2022-02-28 | -$221.03M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | -$76.39M 10-Q · filed 2021-05-06 | -$140.84M derived: sum of 2 quarters · filed 2022-02-28 | -$189.32M derived: sum of 3 quarters · filed 2022-02-28 | -$223.10M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$64.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$112.93M derived: sum of 2 quarters · filed 2022-02-28 | -$146.71M derived: sum of 3 quarters · filed 2022-02-28 | -$175.27M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$48.47M 10-Q · filed 2020-11-10 | -$82.26M derived: sum of 2 quarters · filed 2020-11-10 | -$110.82M 10-Q · filed 2020-11-10 | -$137.18M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | -$33.78M 10-Q · filed 2020-08-11 | -$62.34M 10-Q · filed 2020-08-11 | -$88.71M derived: sum of 3 quarters · filed 2021-02-25 | -$122.19M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$28.56M 10-Q · filed 2020-05-12 | -$54.93M derived: sum of 2 quarters · filed 2021-02-25 | -$88.41M derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$26.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$59.85M derived: sum of 2 quarters · filed 2021-02-25 | -$115.90M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$33.48M 10-Q · filed 2019-11-19 | -$89.53M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | -$69.85M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |